Europe Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2032

TABLE OF CONTENTS

1 INTRODUCTION 23

• 1.1 OBJECTIVES OF THE STUDY 23
• 1.2 MARKET DEFINITION 23
• 1.3 OVERVIEW OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 23
• 1.4 CURRENCY AND PRICING 25
• 1.5 LIMITATIONS 25
• 1.6 MARKETS COVERED 25

2 MARKET SEGMENTATION 27

• 2.1 MARKETS COVERED 27
• 2.2 GEOGRAPHICAL SCOPE 28
• 2.3 YEARS CONSIDERED FOR THE STUDY 29
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
• 2.6 MULTIVARIATE MODELLING 34
• 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 34
• 2.8 MARKET END USER COVERAGE GRID 35
• 2.9 DBMR MARKET POSITION GRID 36
• 2.10 VENDOR SHARE ANALYSIS 37
• 2.11 SECONDARY SOURCES 38
• 2.12 ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 41

• 4.1 PESTEL'S MODEL 42
• 4.2 PORTER'S FIVE FORCES MODEL 43
• 4.3 PRICING ANALYSIS 43

5 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: REGULATIONS 45

• 5.1 REGULATIONS IN U.S. 45
• 5.2 REGULATTIONS IN EUROPE 46
• 5.3 REGULATTIONS IN AUSTRALIA 46
• 5.4 REGULATIONS IN SOUTH AFRICA 46
• 5.5 REGULATIONS IN BRAZIL 47 

6 MARKET OVERVIEW 48

• 6.1 DRIVERS 50
  • 6.1.1 INCREASING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) DISEASE 50
  • 6.1.2 INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER 50
  • 6.1.3 RISING AWARENESS FOR DMD TREATMENTS 51
  • 6.1.4 INCREASE IN THE NUMBER OF CLINICAL TRIALS IS A RECENT TREND 52
• 6.2 RESTRAINTS 53
  • 6.2.1 LIMITED AVAILABILITY OF DMD TREATMENTS DUE TO LACK OF ADVANCE TECHNOLOGY 53
  • 6.2.2 HIGH TREATMENT COST OF DMD DISORDER 54
• 6.3 OPPORTUNITIES 55
  • 6.3.1 DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE AND INCREASING INVESTMENT 55
  • 6.3.2 RISING PATIENT INCLINATION TOWARDS PERSONALIZED AND EFFECTIVE THERAPIES 55
  • 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 56
  • 6.3.4 SUPPORT FROM PATIENT ADVOCACY GROUPS ON THE REGULATORY APPROVAL PROCESS 56
• 6.4 CHALLENGES 57
  • 6.4.1 LACK OF STANDARDIZATION IN DMD DIAGNOSIS 57
  • 6.4.2 ETHICAL CONSIDERATIONS RELATED TO PERMANENT ALTERATION OF A PATIENT'S GENETIC CODE 58

7 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE 59

• 7.1 OVERVIEW 60
• 7.2 MOLECULAR-BASED THERAPIES 63
  • 7.2.1 ANTISENSE OLIGONUCLEOTIDE THERAPY 64
    • 7.2.1.1 EXONDYS 51 64
    • 7.2.1.2 AMONDYS 45 65
    • 7.2.1.3 VYONDYS 53 65
• 7.3 NONSENSE MUTATION 65
  • 7.3.1.1 Translarna 65
• 7.4 STEROID THERAPY 66
  • 7.4.1 PREDNISONE 66
  • 7.4.2 DEFLAZACORT 66
• 7.5 OTHERS 67

8 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY 68

• 8.1 OVERVIEW 69
• 8.2 EXON SKIPPING APPROACH 72
  • 8.2.1 MULTI-EXON SKIPPING APPROACH 72
  • 8.2.2 SINGLE-EXON SKIPPING APPROACH 73
• 8.3 MUTATION SUPPRESSION 73
• 8.4 DYSTROPHIN-TARGETED THERAPIES 74
  • 8.4.1 GENE THERAPIES 74
  • 8.4.2 CELL THERAPIES 75
    • 8.4.2.1 Gene Editing 75
    • 8.4.2.2 Gene Addition 75

9 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 76

• 9.1 OVERVIEW 77
• 9.2 PARENTERAL 80
• 9.3 ORAL 81
• 9.4 OTHERS 82

10 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER 83

• 10.1 OVERVIEW 84
• 10.2 HOSPITALS 87
• 10.3 SPECIALTY CLINICS 88
• 10.4 HOMECARE 89
• 10.5 OTHERS 90

11 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 91

• 11.1 OVERVIEW 92
• 11.2 HOSPITAL PHARMACY 95
• 11.3 RETAIL PHARMACY 96
• 11.4 ONLINE PHARMACY 97

12 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION 98

• 12.1 EUROPE 100
  • 12.1.1 GERMANY 106
  • 12.1.2 FRANCE 111
  • 12.1.3 U.K. 116
  • 12.1.4 ITALY 121
  • 12.1.5 SPAIN 126
  • 12.1.6 RUSSIA 131
  • 12.1.7 TURKEY 136
  • 12.1.8 BELGIUM 141
  • 12.1.9 NETHERLANDS 146
  • 12.1.10 SWITZERLAND 151
  • 12.1.11 REST OF EUROPE 156

13 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 157

• 13.1 COMPANY SHARE ANALYSIS: EUROPE 157

14 SWOT ANALYSIS 158

15 COMPANY PROFILES 159

• 15.1 SAREPTA THERAPEUTICS, INC. 159
  • 15.1.1 COMPANY SNAPSHOT 159
  • 15.1.1 REVENUE ANALYSIS 160
  • 15.1.2 COMPANY SHARE ANALYSIS 160
  • 15.1.3 PRODUCT PORTFOLIO 161
  • 15.1.4 PIPELINE PORTFOLIO 161
  • 15.1.5 RECENT DEVELOPMENTS 161
• 15.2 F. HOFFMANN-LA ROCHE LTD 163
  • 15.2.1 COMPANY SNAPSHOT 163
  • 15.2.2 REVENUE ANALYSIS 163
  • 15.2.3 COMPANY SHARE ANALYSIS 164
  • 15.2.4 PRODUCT PORTFOLIO 164
  • 15.2.5 PIPELINE PORTFOLIO 164
  • 15.2.6 RECENT DEVELOPMENTS 164
• 15.3 PTC THERAPEUTICS. 165
  • 15.3.1 COMPANY SNAPSHOT 165
  • 15.3.2 REVENUE ANALYSIS 165
  • 15.3.3 COMPANY SHARE ANALYSIS 166
  • 15.3.4 PRODUCT PORTFOLIO 166
  • 15.3.5 RECENT DEVELOPMENT 166
• 15.4 PFIZER INC. 167
  • 15.4.1 COMPANY SNAPSHOT 167
  • 15.4.2 REVENUE ANALYSIS 167
  • 15.4.3 COMPANY SHARE ANALYSIS 168
  • 15.4.4 PIPELINE PORTFOLIO 168
  • 15.4.5 PRODUCT PORTFOLIO 168
  • 15.4.6 RECENT DEVELOPMENT 168
• 15.5 AKASHI RX 169
  • 15.5.1 COMPANY SNAPSHOT 169
  • 15.5.2 PIPELINE PORTFOLIO 169
  • 15.5.3 RECENT DEVELOPMENTS 169
• 15.6 AVIDITY BIOSCIENCES 170
  • 15.6.1 COMPANY SNAPSHOT 170
  • 15.6.2 REVENUE ANALYSIS 170
  • 15.6.3 PIPELINE PORTFOLIO 171
  • 15.6.4 RECENT DEVELOPMENTS 171
• 15.7 BIOMARIN 172
  • 15.7.1 COMPANY SNAPSHOT 172
  • 15.7.2 REVENUE ANALYSIS 172
  • 15.7.3 PIPELINE PORTFOLIO 173
  • 15.7.4 RECENT DEVELOPMENTS 173
• 15.8 CAPRICOR THERAPEUTICS, INC. 174
  • 15.8.1 COMPANY SNAPSHOT 174
  • 15.8.2 PIPELINE PORTFOLIO 174
  • 15.8.3 RECENT DEVELOPMENTS 175
• 15.9 DYNE THERAPEUTICS 176
  • 15.9.1 COMPANY SNAPSHOT 176
  • 15.9.2 PIPELINE PORTFOLIO 176
  • 15.9.3 RECENT DEVELOPMENTS 177
• 15.10 FIBROGEN, INC. 178
  • 15.10.1 COMPANY SNAPSHOT 178
  • 15.10.2 REVENUE ANALYSIS 178
  • 15.10.3 PIPELINE PORTFOLIO 179
  • 15.10.4 RECENT DEVELOPMENT 179
• 15.11 ITALFARMACO S.P.A. 180
  • 15.11.1 COMPANY SNAPSHOT 180
  • 15.11.2 PIPELINE PORTFOLIO 180
  • 15.11.3 RECENT DEVELOPMENT 180
• 15.12 NS PHARMA, INC. 181
  • 15.12.1 COMPANY SNAPSHOT 181
  • 15.12.2 PIPELINE PORTFOLIO 181
  • 15.12.3 RECENT DEVELOPMENTS 182
• 15.13 REVERAGEN BIOPHARMA, INC. 183
  • 15.13.1 COMPANY SNAPSHOT 183
  • 15.13.2 PIPELINE PORTFOLIO 183
  • 15.13.3 RECENT DEVELOPMENT 183
• 15.14 SANTHERA PHARMACEUTICALS 184
  • 15.14.1 COMPANY SNAPSHOT 184
  • 15.14.2 REVENUE ANALYSIS 184
  • 15.14.3 PIPELINE PORTFOLIO 185
  • 15.14.4 RECENT DEVELOPMENT 185
• 15.15 TAIHO PHARMACEUTICAL CO., LTD. 186
  • 15.15.1 COMPANY SNAPSHOT 186
  • 15.15.2 PIPELINE PORTFOLIO 186
  • 15.15.3 RECENT DEVELOPMENTS 186
• 15.16 SOLID BIOSCIENCES INC. 187
  • 15.16.1 COMPANY SNAPSHOT 187
  • 15.16.2 PIPELINE PORTFOLIO 187
  • 15.16.3 RECENT DEVELOPMENT 187
• 15.17 STEALTH BIOTHERAPEUTICS INC 188
  • 15.17.1 COMPANY SNAPSHOT 188
  • 15.17.2 PIPELINE PORTFOLIO 188
  • 15.17.3 RECENT DEVELOPMENT 188

16 QUESTIONNAIRE 189

17 RELATED REPORTS 192

LIST OF TABLES

• TABLE 1 LIST OF PRICES FOR APPROVED DRUGS OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 44
• TABLE 2 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE , 2021-2030 (USD THOUSAND) 63
• TABLE 3 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
• TABLE 4 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
• TABLE 5 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
• TABLE 6 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 65
• TABLE 7 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
• TABLE 8 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 66
• TABLE 9 EUROPE OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
• TABLE 10 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 71
• TABLE 11 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
• TABLE 12 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 72
• TABLE 13 EUROPE MUTATION SUPPRESSION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
• TABLE 14 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
• TABLE 15 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 74
• TABLE 16 EUROPE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 75
• TABLE 17 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND) 79
• TABLE 18 EUROPE PARENTERAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
• TABLE 19 EUROPE ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
• TABLE 20 EUROPE OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
• TABLE 21 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND) 86
• TABLE 22 EUROPE HOSPITALS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
• TABLE 23 EUROPE SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
• TABLE 24 EUROPE HOMECARE IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
• TABLE 25 EUROPE OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
• TABLE 26 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
• TABLE 27 EUROPE HOSPITAL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
• TABLE 28 EUROPE RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
• TABLE 29 EUROPE ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
• TABLE 30 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 100
• TABLE 31 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 32 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 33 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
• TABLE 34 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 102
• TABLE 35 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
• TABLE 36 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 102
• TABLE 37 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
• TABLE 38 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 103
• TABLE 39 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
• TABLE 40 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 103
• TABLE 41 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 104
• TABLE 42 EUROPE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 104
• TABLE 43 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 104
• TABLE 44 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
• TABLE 45 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
• TABLE 46 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 47 GERMANY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 48 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
• TABLE 49 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 107
• TABLE 50 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 107
• TABLE 51 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
• TABLE 52 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 107
• TABLE 53 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 108
• TABLE 54 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 108
• TABLE 55 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 108
• TABLE 56 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 108
• TABLE 57 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 109
• TABLE 58 GERMANY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 109
• TABLE 59 GERMANY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 109
• TABLE 60 GERMANY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 109
• TABLE 61 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 110
• TABLE 62 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
• TABLE 63 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 110
• TABLE 64 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
• TABLE 65 FRANCE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
• TABLE 66 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
• TABLE 67 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 112
• TABLE 68 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 112
• TABLE 69 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 112
• TABLE 70 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 112
• TABLE 71 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 113
• TABLE 72 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
• TABLE 73 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 113
• TABLE 74 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 113
• TABLE 75 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 114
• TABLE 76 FRANCE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 114
• TABLE 77 FRANCE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 114
• TABLE 78 FRANCE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 114
• TABLE 79 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 115
• TABLE 80 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 115
• TABLE 81 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 115
• TABLE 82 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
• TABLE 83 U.K. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
• TABLE 84 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 116
• TABLE 85 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 117
• TABLE 86 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 117
• TABLE 87 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 117
• TABLE 88 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 117
• TABLE 89 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 118
• TABLE 90 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 118
• TABLE 91 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 118
• TABLE 92 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 118
• TABLE 93 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 119
• TABLE 94 U.K. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 119
• TABLE 95 U.K. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 119
• TABLE 96 U.K. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 119
• TABLE 97 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 120
• TABLE 98 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
• TABLE 99 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 120
• TABLE 100 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
• TABLE 101 ITALY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
• TABLE 102 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
• TABLE 103 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 122
• TABLE 104 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 122
• TABLE 105 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
• TABLE 106 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 122
• TABLE 107 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 123
• TABLE 108 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 123
• TABLE 109 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 123
• TABLE 110 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 123
• TABLE 111 ITALYDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 124
• TABLE 112 ITALY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 124
• TABLE 113 ITALY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 124
• TABLE 114 ITALY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 124
• TABLE 115 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 125
• TABLE 116 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 125
• TABLE 117 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 125
• TABLE 118 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
• TABLE 119 SPAIN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
• TABLE 120 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
• TABLE 121 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 127
• TABLE 122 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 127
• TABLE 123 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 127
• TABLE 124 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 127
• TABLE 125 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 128
• TABLE 126 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
• TABLE 127 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 128
• TABLE 128 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 128
• TABLE 129 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 129
• TABLE 130 SPAIN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 129
• TABLE 131 SPAIN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 129
• TABLE 132 SPAIN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 129
• TABLE 133 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 130
• TABLE 134 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 130
• TABLE 135 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 130
• TABLE 136 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
• TABLE 137 RUSSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
• TABLE 138 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
• TABLE 139 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 132
• TABLE 140 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 132
• TABLE 141 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
• TABLE 142 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 132
• TABLE 143 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 133
• TABLE 144 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 133
• TABLE 145 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 133
• TABLE 146 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 133
• TABLE 147 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 134
• TABLE 148 RUSSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 134
• TABLE 149 RUSSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 134
• TABLE 150 RUSSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 134
• TABLE 151 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 135
• TABLE 152 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 135
• TABLE 153 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 135
• TABLE 154 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
• TABLE 155 TURKEY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
• TABLE 156 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
• TABLE 157 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 137
• TABLE 158 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 137
• TABLE 159 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 137
• TABLE 160 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 137
• TABLE 161 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 138
• TABLE 162 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
• TABLE 163 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 138
• TABLE 164 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 138
• TABLE 165 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 139
• TABLE 166 TURKEY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 139
• TABLE 167 TURKEY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 139
• TABLE 168 TURKEY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 139
• TABLE 169 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 140
• TABLE 170 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 140
• TABLE 171 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 140
• TABLE 172 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
• TABLE 173 BELGIUM MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
• TABLE 174 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
• TABLE 175 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 142
• TABLE 176 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 142
• TABLE 177 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
• TABLE 178 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 142
• TABLE 179 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 143
• TABLE 180 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
• TABLE 181 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 143
• TABLE 182 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 143
• TABLE 183 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 144
• TABLE 184 BELGIUM EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 144
• TABLE 185 BELGIUM DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 144
• TABLE 186 BELGIUM CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 144
• TABLE 187 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 145
• TABLE 188 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 145
• TABLE 189 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
• TABLE 190 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
• TABLE 191 NETHERLANDS MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
• TABLE 192 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
• TABLE 193 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
• TABLE 194 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 147
• TABLE 195 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
• TABLE 196 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
• TABLE 197 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 148
• TABLE 198 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 148
• TABLE 199 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 148
• TABLE 200 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 148
• TABLE 201 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
• TABLE 202 NETHERLANDS EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
• TABLE 203 NETHERLANDS DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
• TABLE 204 NETHERLANDS CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
• TABLE 205 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 150
• TABLE 206 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
• TABLE 207 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 150
• TABLE 208 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
• TABLE 209 SWITZERLAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
• TABLE 210 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
• TABLE 211 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
• TABLE 212 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 152
• TABLE 213 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
• TABLE 214 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
• TABLE 215 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
• TABLE 216 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 153
• TABLE 217 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 153
• TABLE 218 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
• TABLE 219 SWITZERLANDDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
• TABLE 220 SWITZERLAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
• TABLE 221 SWITZERLAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
• TABLE 222 SWITZERLAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
• TABLE 223 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 155
• TABLE 224 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
• TABLE 225 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
• TABLE 226 REST OF EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156

LIST OF FIGURES

• FIGURE 1 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 27
• FIGURE 2 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DATA TRIANGULATION 30
• FIGURE 3 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DROC ANALYSIS 31
• FIGURE 4 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 32
• FIGURE 5 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 32
• FIGURE 6 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 33
• FIGURE 7 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: MARKET END USER COVERAGE GRID 35
• FIGURE 8 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DBMR MARKET POSITION GRID 36
• FIGURE 9 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: VENDOR SHARE ANALYSIS 37
• FIGURE 10 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 40
• FIGURE 11 THE RISING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) AND INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET FROM 2023 TO 2030 41
• FIGURE 12 MOLECULAR-BASED THERAPIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET IN 2023 AND 2030 41
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 49
• FIGURE 14 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , 2022 60
• FIGURE 15 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 61
• FIGURE 16 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , CAGR (2023-2030) 61
• FIGURE 17 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 62
• FIGURE 18 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2022 69
• FIGURE 19 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2023-2030 (USD THOUSAND) 70
• FIGURE 20 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, CAGR (2023-2030) 70
• FIGURE 21 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, LIFELINE CURVE 71
• FIGURE 22 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 77
• FIGURE 23 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 78
• FIGURE 24 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 78
• FIGURE 25 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 79
• FIGURE 26 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2022 84
• FIGURE 27 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 85
• FIGURE 28 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, CAGR (2023-2030) 85
• FIGURE 29 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, LIFELINE CURVE 86
• FIGURE 30 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 92
• FIGURE 31 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 93
• FIGURE 32 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 93
• FIGURE 33 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
• FIGURE 34 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SNAPSHOT 99
• FIGURE 35 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 157